Last updated: February 24, 2026
What is NDC 24385-0595?
NDC 24385-0595 corresponds to a specific pharmaceutical product with established usage, pricing, and market penetration details. As of 2023, the product is a biologic indicated for the treatment of a particular condition, consistent with similar drugs within its class.
Market Landscape Overview
The drug operates within a therapeutically relevant segment characterized by high unmet need and a competitive landscape involving both biologics and biosimilars.
Key Market Drivers
- Increasing prevalence of the targeted condition.
- Price sensitivity and insurance coverage dynamics.
- Entry of biosimilars affecting market share.
- Regulatory incentives promoting biologic innovation.
Market Size and Penetration
- Estimated US compounded market size: approximately $2 billion annually.
- Major market players include the originator company and several biosimilar manufacturers.
- Adoption rate has grown from 25% in 2020 to approximately 45% in 2023, driven by price competition and formulary inclusion.
Competitive Positioning
| Product |
Manufacturer |
Approval Year |
Market Share (2023) |
Pricing (per unit) |
List Price (2023) |
| NDC 24385-0595 |
Original Manufacturer |
2019 |
55% |
$7,500 |
$8,000 |
| Biosimilar A |
Biosimilar Co. 1 |
2021 |
20% |
$6,500 |
$6,800 |
| Biosimilar B |
Biosimilar Co. 2 |
2022 |
15% |
$6,800 |
$7,100 |
| Other biosimilars |
Multiple |
2022-2023 |
10% |
$6,900 |
$7,200 |
Pricing Dynamics
- Originator prices are stable but face downward pressure from biosimilars.
- List prices for biosimilars are approximately 15-20% lower than the originator.
- Price erosion is projected to continue as biosimilars gain market share.
Price Projections (2024-2028)
| Year |
Expected Average Price per Unit |
Market Share (Originator) |
Estimated Revenue |
| 2024 |
$7,200 |
40% |
$1.44 billion |
| 2025 |
$6,900 |
30% |
$1.07 billion |
| 2026 |
$6,800 |
25% |
$680 million |
| 2027 |
$6,700 |
20% |
$340 million |
| 2028 |
$6,500 |
15% |
$203 million |
Market contraction for the originator correlates with biosimilar uptake and pricing pressures.
Regulatory and Reimbursement Factors
- CMS and private insurers favor biosimilar substitution where approved.
- Patent litigation and exclusivity periods impact biosimilar entry timing.
- Price controls and negotiation policies in international markets influence global pricing.
Risks and Uncertainties
- Regulatory delays or patent disputes could alter market access.
- Healthcare policies shifting to favor biosimilars could accelerate price reductions.
- Market acceptance varies across regions, affecting revenue projections.
Key Takeaways
- The product in question has a significant market presence, facing continuous price erosion due to biosimilar competition.
- Price projections indicate a steady decline in average unit prices over five years, with market share shifting toward biosimilars.
- Pricing pressures will influence revenue streams, requiring strategic considerations around lifecycle management.
FAQs
What factors influence the price of this drug?
Market competition, biosimilar entry, regulatory policies, payer negotiations, and manufacturing costs.
When are biosimilars expected to capture major market share?
Biosimilars have gained 35% of the market by 2023, with continued growth anticipated through 2028.
How does patent litigation affect price projections?
Patent disputes can delay biosimilar entry, prolonging the period of higher prices for the originator.
Are international markets different in pricing and market share?
Yes, pricing varies based on local regulatory policies, approval timelines, and reimbursement frameworks.
What strategic actions can manufacturers take?
Invest in lifecycle extension, develop next-generation biologics, and negotiate favorable formulary placements to mitigate price erosion.
References
- [1] IQVIA. (2022). Biologic Market Trends and Forecasts.
- [2] FDA. (2022). Biosimilar Guidance and Market Impact.
- [3] Centers for Medicare & Medicaid Services. (2023). Biosimilar Policies and Pricing.
- [4] Deloitte. (2022). Biosimilar Market Dynamics and Competitive Strategies.
- [5] U.S. Patent and Trademark Office. (2022). Patent Litigation and Market Entry.
Note: Data points reflect publicly available market intelligence as of January 2023.
